1. Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R
- Author
-
Franck, Morschhauser, Loretta, Nastoupil, Pierre, Feugier, Jean-Marc, Schiano de Colella, Hervé, Tilly, Maria Lia, Palomba, Emmanuel, Bachy, Christophe, Fruchart, Edward N, Libby, Rene-Olivier, Casasnovas, Ian W, Flinn, Corinne, Haioun, Hervé, Maisonneuve, Loic, Ysebaert, Nancy L, Bartlett, Kamal, Bouabdallah, Pauline, Brice, Vincent, Ribrag, Steven, Le Gouill, Nicolas, Daguindau, Stéphanie, Guidez, Gian Matteo, Pica, Alejandro Martín, García-Sancho, Armondo, López-Guillermo, Jean-François, Larouche, Kiyoshi, Ando, Maria, Gomes da Silva, Marc, André, Wu, Kalung, Laurie H, Sehn, Koji, Izutsu, Guillaume, Cartron, Argyrios, Gkasiamis, Russell, Crowe, Luc, Xerri, Nathan H, Fowler, and Gilles, Salles
- Subjects
Survival Rate ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Neoplasms, Second Primary ,Rituximab ,Lenalidomide ,Lymphoma, Follicular - Published
- 2022